Simple pharma investement project evaluation: we suppose that a pharmaceutical firm needs to evaluate the value of development of a new product. The project is already started (it is in the first clinical stage) and, at time 0, the company wants to know the value of the opportunity to invest in the last stage of clinical trials and also to understand the interactions among options to abandon development and to expand the market. See the
fairmat model.